Celgene Corp (CELG) Tops Q2 EPS by 1c; Raises Guidance

Celgene Corp (NASDAQ: CELG) reported Q2 EPS of $0.90, $0.01 better than the analyst estimate of $0.89. Revenue for the quarter came in at $1.87 billion versus the consensus estimate of $1.85 billion.

Celgene Corp sees FY2014 EPS of $3.60-$3.65, versus prior guidance of $3.50-$3.60 and the consensus of $3.67. Celgene Corp sees FY2014 revenue of $7.6 billion, versus prior guidance of $7.54 billion and the consensus of $7.5 billion.

“Strong second quarter operating and financial results demonstrate the significant momentum of our portfolio and support raising our 2014 guidance,” said Bob Hugin, Chairman and Chief Executive Officer of Celgene Corporation. “We look forward to multiple milestones in the second half of the year, including the expansion of OTEZLA® into psoriasis and the further advancement of our pipeline.”

For earnings history and earnings-related data on Celgene Corp (CELG) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• JD.com (JD) Reiterated at Buy by Benchmark Amid Earnings Recovery
• SVB & T Corporation (SVBT) Tops Q2 EPS by 275c